Your session is about to expire
← Back to Search
Canakinumab injection; spartalizumab, nab-paclitaxel, gemcitabine for Pancreatic Cancer (PanCAN-SR1 Trial)
PanCAN-SR1 Trial Summary
This trial is testing a new four-drug combination to see if it is safe and effective. The combination includes two different kinds of antibodies and two chemotherapy drugs.
- Pancreatic Cancer
PanCAN-SR1 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.PanCAN-SR1 Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Have the FDA granted approval to Canakinumab injection, spartalizumab, nab-paclitaxel and gemcitabine?
"Our in-house team at Power has assigned a safety score of 1 to canakinumab injection; spartalizumab, nab-paclitaxel, gemcitabine due to the limited data available from early phase clinical trials."
What is the upper limit for participants in this medical trial?
"Sadly, this clinical trial is no longer accepting applicants. It was first posted on November 2nd 2020 and the last update to its listing occurred on April 5th 2022. However, if you are interested in other trials, 771 studies that involve adenocarcinoma are currently enrolling patients while 1149 research projects related to Canakinumab injection; spartalizumab, nab-paclitaxel, gemcitabine have open positions available right now."
Has Canakinumab injection, spartalizumab, nab-paclitaxel and gemcitabine been implemented in any prior research studies?
"Since 1997, canakinumab injection; spartalizumab, nab-paclitaxel and gemcitabine have been looked at in numerous clinical trials. City of Hope Comprehensive Cancer Center was the site of first examination. To date, there are 1931 completed studies with 1149 still active ones primarily situated in Boston, MA."
To what illnesses are Canakinumab injection, spartalizumab, nab-paclitaxel, and gemcitabine typically employed as a remedy?
"Canakinumab injection; spartalizumab, nab-paclitaxel, gemcitabine is the conventional treatment for active systemic juvenile idiopathic arthritis. This drug combination can also help treat other medical issues such as prior anthracycline exposure, metastatic neoplasms and locally advanced non-small cell lung cancer."
Are there any vacancies for participants in this clinical experiment?
"Unfortunately, this clinical trial is not presently accepting participants; it was initially listed on November 2nd 2020 and last updated April 5th 2022. If you are still looking for other trials to take part in, 771 studies involving adenocarcinoma treatment are currently recruiting patients as well as 1,149 research projects that require the administration of Canakinumab injection with spartalizumab or nab-paclitaxel alongside gemcitabine."
Share this study with friends
Copy Link
Messenger